Nucleocytoplasmic β‐catenin expression contributes to neuroendocrine differentiation in muscle invasive bladder cancer

Abstract

AbstractBladder cancers are heterogeneous in nature, showing diverse molecular profiles and histopathological characteristics, which pose challenges for diagnosis and treatment. However, understanding the molecular basis of such heterogeneity has remained elusive. This study aimed to elucidate the molecular landscape of neuroendocrine‐like bladder tumors, focusing on the involvement of β‐catenin localization. Analyzing the transcriptome data and benefiting from the molecular classification tool, we undertook an in‐depth analysis of muscle‐invasive bladder cancers to uncover the molecular characteristics of the neuroendocrine‐like differentiation. The study explored the contribution of transcription factors and chromatin remodeling complexes to neuroendocrine differentiation in bladder cancer. The study revealed a significant correlation between β‐catenin localization and neuroendocrine differentiation in muscle‐invasive bladder tumors, highlighting the molecular complexity of neuroendocrine‐like tumors. Enrichment of YY1 transcription factor, E2F family members, and Polycomb repressive complex components in β‐catenin‐positive tumors suggest their potential contribution to neuroendocrine phenotypes. Our findings contribute valuable insights into the molecular complexity of neuroendocrine‐like bladder tumors. By identifying potential therapeutic targets and refining diagnostic strategies, this study advances our understanding of endocrinology in the context of bladder cancer. Further investigations into the functional implications of these molecular relationships are warranted to enhance our knowledge and guide future therapeutic interventions.